Aptar's Nasal Delivery Technology Advances CastleVax Phase II COVID-19 Vaccine Trial
核心洞察
Aptar's LuerVax (搜索)® and Spray Divider (搜索)™ nasal delivery systems are being utilized in CastleVax (搜索)'s Phase II clinical trial of CVAX-01, an intranasal COVID-19 (搜索) vaccine candidate.
The Phase II study will evaluate safety, tolerability, and immune response in approximately 200 U.S. adults, comparing the intranasal vaccine to FDA-approved injectable mRNA vaccines.
The collaboration highlights Aptar's position as a leader in nasal vaccine delivery systems and demonstrates the potential for mucosal immunity through intranasal vaccination approaches.
AptarGroup has announced that its innovative nasal vaccine delivery solutions are being utilized in CastleVax (搜索)'s Phase II clinical trial of CVAX-01, a next-generation intranasal COVID-19 (搜索) vaccine candidate. The collaboration represents a significant milestone in advancing nasal vaccine delivery technologies and novel immunization strategies.
Phase II Trial Design and Objectives
The Phase II study of CVAX-01 is designed to assess the safety, tolerability and systemic and mucosal immune response of CastleVax (搜索)'s intranasal COVID-19 (搜索) vaccine compared to an FDA-approved injectable mRNA vaccine. The trial will enroll approximately 200 U.S. adults, including high-risk individuals and those over 65 years of age, who will be followed for six months to evaluate whether nasal delivery can provide strong mucosal immunity.
Advanced Delivery Technology Platform
Aptar's contribution to the trial centers on two key nasal delivery technologies: LuerVax (搜索)® and Spray Divider (搜索)™. These innovative solutions support the company's commitment to advancing drug delivery and next-generation vaccine development, backed by comprehensive regulatory and technical expertise.
The collaboration reinforces Aptar's position as a trusted partner in the evolving landscape of nasal vaccine delivery systems. The company leverages its deep expertise in regulatory pathways, technical support, and innovative device design to support pharmaceutical partners in accelerating development and bringing cutting-edge solutions to market.
Comprehensive Development Support
Aptar provides extensive support throughout the nasal drug development journey, from system design and formulation compatibility to clinical trial support and regulatory guidance. The company's Pharma Services platform offers expertise in combination products, device/formulation optimization, and critical testing such as extractables and leachables, helping partners manage development risks and accelerate time-to-market.
"Our collaboration on CastleVax (搜索)'s Phase II trial reflects why leading innovators choose Aptar as their trusted partner for next-generation medicine development and advanced drug delivery," said Alex Theodorakis, President, Aptar Pharma (搜索) Prescription. "By offering comprehensive regulatory guidance and technical support, we help our customers navigate complexity with confidence and accelerate the delivery of life-changing therapies to patients worldwide."
Strategic Positioning in Vaccine Innovation
This partnership underscores the growing interest in intranasal vaccine delivery as a potentially superior approach to traditional injectable vaccines, particularly for respiratory pathogens like COVID-19 (搜索). The ability to generate mucosal immunity at the site of viral entry represents a significant advancement in vaccine technology, with the potential to provide more comprehensive protection against infection and transmission.
Aptar, headquartered in Crystal Lake, Illinois, operates as a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, with over 13,000 dedicated employees across 20 countries. The company serves multiple end markets including pharmaceutical, beauty, food, beverage, personal care and home care sectors.